Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Trial Profile

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2017

At a glance

  • Drugs MAGE A3 6 specific t cells (Primary) ; NTBI 1301 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Adaptimmune
  • Most Recent Events

    • 13 Mar 2017 Planned primary completion date changed from 1 May 2021 to 1 May 2018.
    • 07 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 11 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top